High risk groups 1–3

  • People exposed to occupational and environmental dusts, chemicals and airborne hazards
  • Aboriginal and Torres Strait Islander people and those from culturally and
    linguistically diverse backgrounds
  • Smokers and ex-smokers of tobacco and e-cigarette products

Considerations in pregnancy

  • Pregnant women with airway disease should be seen by a specialist

Urgent referral

1. What is chronic obstructive pulmonary disease (COPD)? 1–3

  • A lung condition characterised by chronic respiratory symptoms (dyspnoea, cough, sputum production) due to abnormalities of the airways (bronchitis, bronchiolitis, emphysema) that cause persistent and progressive airflow obstruction
  • The primary contributing factor is exposure to tobacco smoke. See Smoking cessation
  • All comorbid chronic conditions increase the risk of poor lung function and death

2. Diagnosis of COPD 1–3

  • A diagnosis should be considered in any patient who has:
    • a history of recurrent lower respiratory tract infections
    • exposure to tobacco smoke or occupational or environmental dusts, vapours, fumes and gases
    • breathlessness that is persistent, progresses over time and worsens with exercise
    • chronic cough and sputum production +/- recurrent chest infections
    • forced expiratory post-bronchodilator FEV1/FVC ratio < 0.70 (airflow limitation)
  • Some people present with worsening breathlessness, a cough +/- sputum production or limitation to activity
  • Identifying the airflow limitation and symptoms helps to classify COPD severity. See Table 1. to determine:
    • its impact on patient health
    • the risk of future exacerbations, hospital presentations or death
    • management and treatment

Table 1. Classification of COPD according to airflow obstruction1,2

Stages

Mild

Moderate

Severe

Symptoms

  • Few symptoms
  • Breathless on moderate exertion
  • Cough and sputum production
  • Little or no effect on daily activities
  • Breathless walking on level ground
  • Increasing limitation of daily activities
  • Recurrent chest infections
  • Exacerbations requiring oral corticosteroids and/or ABs
  • Breathless on minimal exertion
  • Daily activities severely impacted
  • Increasing frequency and severity of exacerbations

Lung Function

FEV1 ≈ 60-80% predicted

FEV1 ≈ 40-59% predicted

FEV1 < 40% predicted

3. Management of COPD 1,2

  • Management goals are to:
    • reduce symptoms to improve exercise tolerance and health status
    • reduce risk of exacerbations to prevent disease progression and mortality
    • encourage those who smoke to stop. See Smoking cessation
    • identifying and addressing comorbidities, in particular:
      • any respiratory conditions including Asthma (adults and children > 12) and Bronchiectasis, any cardiac conditions including Heart failure, Hypertension, and Rheumatic heart disease
      • Diabetes
      • Osteoporosis
  1. Support patient self-management 1–3
    • Support the patient with lifestyle modification with particular attention to
      Smoking cessation and pulmonary rehabilitation. See 3.13 Pulmonary rehabilitation program
    • Provide COPD education (Resource 1.) and discuss:
      • airway clearance and breathing techniques. See Resource 2.
      • medicine usage, effects and compliance
      • develop a COPD action plan. See below
    • Refer patient to SMoCC, a phone service that supports patients manage their condition. See Resource 3.
    • Encourage the patient to identify barriers to adequate lifestyle modification and
      medical adherence and create goals to overcome those barriers. See Engaging our patients
  2. Social-emotional support 2,3
    • See Social-emotional wellbeing
  3. Action plan 1–3
    • Develop an action plan (Resource 4.) with the patient so they can:
      • recognise and monitor exacerbations and severity. See Table 1.
      • intervene early to prevent exacerbations
      • understand and feel comfortable using it
    • Review and update action plan each visit, especially when changing medicines
  4. Minimising occupational exposure 1–3
    • Discuss minimising exposure to occupational (particularly mining and quarry workers) risk factors including:
      • smoke, gases, vapours and fumes
      • biological and mineral dusts
      • diesel exhaust
      • indoor and outdoor pollutants and chemicals
  5. Monitor health status 1–3
    • According to 5. Cycle of care, regularly monitor:
      • temperature, pulse, respiratory rate, blood pressure, pulse oximetry
      • weight and BMI
      • sputum colour and amount
      • lung function by spirometry before and 10–15 minutes after 4 puffs of salbutamol via a spacer. See Resources 5.
      • ECG for Coronary heart disease changes and right ventricular strain pattern
      • chest x-ray for Bronchiectasis, emphysema, lung hyperinflation, heart failure
      • echocardiogram for pulmonary hypertension
      • swallowing difficulties. Refer to speech pathologist
    • Use the COPD Assessment Test (CAT) to measure the impact of COPD on the patient and changes over time. See Resource 6.
  6. Smoking cessation 1–3
    • Quitting smoking is the most effective means to prevent COPD from progressing
    • Perform spirometry on past or present smokers with recurrent respiratory infections or frequent and unusual sputum production. See Resource 5. and 7.
    • See Smoking cessation
  7. Improve exercise tolerance 1–3
    • Encourage patient to keep as active as possible to maintain lung function
    • Refer to a pulmonary rehabilitation program. See 3.12 Pulmonary rehabilitation program
    • See Physical activity and sleep
  8. Nutrition 1–3
    • Lung disease increases the risk of poor nutrition, weight loss and reduced muscle and bone strength due to:
      • increased energy needs
      • changes in appetite
      • lack of energy to shop, cook or eat meals
      • an increased need for essential vitamins, minerals and antioxidants
    • Refer to dietitian if there is weight loss or weight gain
    • For unintended weight loss, refer to exclude an alternate diagnosis e.g. cancer, diabetes
    • See Diet and nutrition
  9. Sleep hygiene 1–3
    • Medicines, breathing difficulties, anxiety and depression in COPD can disrupt sleep
    • Patients with COPD and OSA have:
      • a higher prevalence of pulmonary hypertension than those without OSA
      • improved survival outcomes and lower rates of hospital admission with CPAP use
    • Assess a patient’s daytime sleepiness and OSA risk by using a validated tool. If they score highly refer to a sleep specialist. See Resource 8.
  10. Prevent respiratory infections 1–4
    • Respiratory illnesses contribute to COPD exacerbations and progression
    • Provide Influenza, pneumococcal, pertussis and COVID-19 vaccines as per the  Australian Immunisation Handbook
  11. Home oxygen 1–3
    • Long term oxygen therapy (18 hours/day) reduces cardiac workload and prolongs survival in patients who have chronic resting arterial hypoxemia:
      • FEV1 < 40% predicted
      • SpO2 < 88%
      • those with pulmonary hypertension
      • PaO2 ≤ 55 mmHg or SpO2 ≤ 88%
      • PaO2 55–59 mmHg or SpO2 with evidence of right heart failure, pulmonary hypertension or high red cell count
    • Home O2 is evaluated by blood gases after 4–8 weeks when the person is stable, to ascertain effectiveness and whether to continue
    • Medical Aids Subsidy Scheme (MASS) can supply home oxygen to eligible patients. See Resource 9.
    • Provide a home visit for oxygen concentrator education
  12. Prevention of complications 1
    • Identify risk factors for Osteoporosis by assessing:
      • vitamin D levels
      • mobilisation
      • use of high dose corticosteroids
      • underlying decreased bone mineral density
      • bone densitometry where appropriate
    • Assess Australian cardiovascular disease risk calculator
    • Pulmonary hypertension:
      • is difficult to treat
      • manifests late due to poor lung ventilation from ongoing exacerbations
      • management relies on smoking cessation, improving diet and physical activity and medicine adherence to prevent right heart failure
  13. Pulmonary rehabilitation program 2
    • Offered to all symptomatic patients with more than 2 exacerbations per year or with moderate to severe COPD to avoid hospitalisation
    • Refer to the Pulmonary Rehabilitation Toolkit. See Resource 10.
    • Refer to an exercise physiologist or the Lung Foundation for rehabilitation program details and/or training. See Resource 11.
  14. Airway clearance technique
    • An early intervention strategy to clear lung secretions and avoid hospitalisation:
      • start with 5 deep abdominal breaths. Expand chest fully, starting with the
        diaphragm and lower ribs. Avoid lifting or shrugging shoulders
      • do 30–60 seconds of relaxed breathing. Breathe from the diaphragm. With a hand feel the stomach rising and falling. Shoulders should be relaxed
      • do another 5 deep abdominal breaths
      • follow this with 30–60 seconds of relaxed breathing
      • take a medium sized breath in and huff the air out a little more forcefully
      • start with 3 cycles of gentle huffs. Finish with 2 cycles of more forceful huffs
      • finish with a cough to clear any secretions left in the main airways
      • repeat the cycle 2–3 times or until no more secretions can be removed
    • Refer to a physiotherapist if patient is unable to clear lung secretions
    • For airway clearance information see Resource 2.
  15. Falls prevention
    • Screen for individual falls risk. See Resource 12.
    • Refer to a balance and strength group by a physiotherapist or exercise physiologist
    • Refer to an occupational therapist to assess for home modification requirements to minimise trip and fall hazards
  16. Palliative support 1–3
    • Consider discussing a palliative approach to care, advance care planning, and end-of-life issues when patient has:
      • predicted FEV1 < 25%
      • dependence on oxygen
      • respiratory or heart failure or other comorbidities
      • weight loss or muscle wasting
      • decreased functional status with increased dependence on others
      • advanced age
      • See Palliative care and Advance Care Planning
    • Refer to physiotherapist or occupational therapist for a home support assessment e.g. wheel chair, bedding, rails etc
    • Refer eligible patients to Home and Community Care (HACC) and MASS services. See Resource 9.

Table 1. Stepwise management of stable COPD 1–3,6

Stepwise management of stable COPD

4. Medicines for COPD

  • Monitor medicine adherence and correct inhaler technique according to product instructions. See Resource 13.
Always use a spacer for metered dose inhalers (pMDI) to reduce local adverse effects and increase delivery of medicine to the airways
  • See Table 1. for a guide to manage stable COPD

Table 2. Medicines for all stages of COPD (continued) 1–3,6

SABA

  • Always use with spacer
  • Takes effect immediately
  • Salbutamol pMDI 100 microgs 2 puffs PRN OR
  • Terbutaline sulphate turbuhaler DPI 500 microgs 1 puff PRN

SAMA

  • Ipratropium is not usually used for symptom relief in COPD, is contraindicated in patients taking a LAMA is more expensive than a SABA, and may increase the risk of cardiovascular events
  • Always use with spacer
  • 20 minutes to take effect but longer lasting than above
  • Ipratropium bromide pMDI 21 microgs 1–2 puffs PRN

LAMA (Non-LAM)

  • Cease ipratropium bromide to avoid double dosing
  • May cause dry mouth, blurred vision, dizziness and urinary retention
  • May rarely precipitate acute angle-closure glaucoma
  • Tiotropium bromide DPI one 18 microgs capsule 1 puff daily OR
  • Umeclidinium bromide DPI 62.5 microgs 1 puff daily OR
  • Glycopyrronium DPI one 50 microgs capsule 1 puff daily OR
  • Aclidinium DPI 322 microgs 1 puff bd

LABA

  • Formoterol DPI 12 microgs 1 puff bd
  • Salmeterol DPI 50 microgs 1 puff bd

Combination ICS/LABA*

  • LAMA with combination ICS/LABA is tolerated
  • To minimise the risk of oropharyngeal candidiasis rinse mouth with water after use
  • Not all inhalers are TGA registered for use in COPD, or listed on the PBS or LAM
  • Salmeterol/Fluticasone DPI or pMDI
    • 250/25 microgs 2 puffs bd
    • 500/50 microgs 1 puff bd
  • Vilanterol/Fluticasone furoate DPI 100/25 microgs 1 puff daily
  • Budesonide/Formoterol DPI
    • 200/6 microgs 2 puffs bd
    • 400/12 microgs 1 puff bd

Oxygen therapy*

  • See 3.10 Home oxygen
  • Long-term low flow oxygen ( > 18 hours per day, between 1–3 L/m via nasal prongs) with a target SpO2 > 88%
  • Caution in patients with PaCO2 > 45 mmHg

Oral corticosteroids

  • A 5 day course of 30–50 mg daily can reduce duration of exacerbations in stable COPD
  • Long term monotherapy is not recommended in COPD

Antibiotics

  • Antibiotic therapy should not be used unless the patient has clinical signs of infection
  • Amoxicillin 500mg tds 5 days OR
  • Doxycycline 100mg daily 5 days

Symptom relief

  • Nebulised 0.9% sodium chloride 5–10 mL qid prn

*See LAM and PBS for medicine indications and restrictions

5. Cycle of care

Cycle of care summary for COPD

COPD severity

Mild

Moderate

Severe

Action

Dx

Review frequency

Height

 

Blood pressure

-

12 mthly

6 mthly

Weight

-

12 mthly

6 mthly

BMI

-

12 mthly

6 mthly

Pulse rate

-

12 mthly

6 mthly

Respiratory rate

-

12 mthly

6 mthly

Temperature

-

12 mthly

6 mthly

Spirometry

-

12 mthly

6 mthly

SpO2

-

12 mthly

6 mthly

PaO2

 

For those on or being considered for home oxygen

CAT score

-

12 mthly

6 mthly

Lifestyle modifications education

Every visit. Specifically smoking cessation, physical activity and diet and nutrition

Social-emotional wellbeing

-

12 mthly

6 mthly

Advance care planning

-

12 mthly

6 mthly

End of life care

-

-

6 mthly

Inhaler puffer technique

Every visit

COPD action plan

Every visit

Influenza, pneumococcal, pertussis and COVID-19 vaccines

See the Australian Immunisation Handbook for schedule

ECG

2 yrly

2 yrly

12 mthly

Chest x-ray

-

If frequent infective exacerbations

Self-monitoring

-

12 mthly

6 mthly

HW/RN review

-

6 mthly

2 mthly

MO/NP review

-

12 mthly

6 mthly

Medicine review

-

12 mthly

12 mthly

Pulmonary rehabilitation

-

Attend

Attend

Physiotherapist

-

12 mthly

12 mthly

Specialist review

-

If frequent infective exacerbations

6. References

7. Resources

  1. Better living with Chronic Obstructive Pulmonary Disease A Patient Guide and The Lung Foundation resources
  2. Airway clearance resource
  3. Self-Management of Chronic Conditions (SMoCC) service
  4. Lung foundation COPD action plan or for Aboriginal or Torres Strait Islander people
  5. The spirometry handbook and training tools and the COPD and spirometry resources
  6. The COPD Assessment Test (CAT)
  7. COPD screening using spirometry
  8. The Epworth Sleepiness Scale and STOP-Bang questionnaire
  9. Access the Medical Aids Subsidy Scheme (MASS) and Queensland Community Support Scheme
  10. The Australian Lung Foundation Pulmonary Rehabilitation Toolkit
  11. The Lung Foundation training and education website
  12. Individual falls risk screening and Queensland Government’s Stay on Your Feet Toolkit
  13. Lung Foundation inhaler use videos and printable instructions and the National Asthma Council